Search our Database of Scientific Publications and Authors

I’m looking for a

    3375 results match your criteria Oral Malignant Melanoma

    1 OF 68

    Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
    Nat Commun 2017 Feb 15;8:14449. Epub 2017 Feb 15.
    Department of Pharmacology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA.
    ETS transcription factors are commonly deregulated in cancer by chromosomal translocation, overexpression or post-translational modification to induce gene expression programs essential in tumorigenicity. Targeted destruction of these proteins may have therapeutic impact. Here we report that Ets-1 destruction is regulated by the deubiquitinating enzyme, Usp9x, and has major impact on the tumorigenic program of metastatic melanoma. Read More

    Analysis of the expression of NLRP3 and AIM2 in periapical lesions with apical periodontitis and microbial analysis outside the apical segment of teeth.
    Arch Oral Biol 2017 Feb 6;78:39-47. Epub 2017 Feb 6.
    Department of Endodontics and Operative Dentistry, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 639, Zhizaoju Road, Shanghai, 200011, China. Electronic address:
    Objective: To detect the distribution and expression levels of the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) and the absent in Melanoma 2 (AIM2) inflammasomes in periapical lesions and to analyse the possible microbial stimuli outside of teeth.

    Design: The distribution of NLRP3 and AIM2 inflammasomes in sixteen periapical lesions was investigated by immunohistochemistry. Meanwhile, the relative gene expression levels of NLRP3 and AIM2 in sixteen periapical lesions and three health periodontal tissue were quantified by real-time polymerase chain reaction (PCR). Read More

    Cutaneous adverse effects of the immune checkpoint inhibitors.
    Curr Probl Cancer 2016 Dec 14. Epub 2016 Dec 14.
    Section of Dermatology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire.
    The immune checkpoint targeted agents, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and anti-programed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitors are frequently associated with cutaneous side effects that are often dose limiting and can lead to discontinuation of therapy. Ipilimumab, a CTLA-4 inhibitor, is most commonly associated with a morbilliform eruption on the trunk and extremities and pruritus. More severe cutaneous toxicities reported include toxic epidermal necrolysis and severe drug rash with eosinophila and systemic symptoms. Read More

    Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1).
    Cancer Discov 2017 Feb 9. Epub 2017 Feb 9.
    Fondazione IRCCS Istituto Nazionale dei Tumori.
    Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two Phase 1 studies in patients with advanced or metastatic solid tumors, including patients with active CNS disease. Here we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions, naïve to prior TKI treatment targeting the specific gene, and who were treated at doses that achieved therapeutic exposures consistent with the RP2D. Entrectinib was well tolerated, with predominantly Grades 1/2 adverse events that were reversible with dose modification. Read More

    Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes.
    Anticancer Res 2017 02;37(2):607-614
    Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Aim: We investigated the therapeutic effects of a mitogen-activated protein (MEK) inhibitor, selumetinib, in a hepatic melanoma metastasis model and studied its possible mechanism of action.

    Materials And Methods: Melanoma cell lines were exposed to selumetinib under different experimental conditions. We established a mouse model of liver metastasis and treated mice orally with vehicle or selumetinib and then evaluated metastasis progress. Read More

    Incidence of lip malignancies in Germany - data from 9 population-based cancer registries.
    J Oral Pathol Med 2017 Feb 8. Epub 2017 Feb 8.
    Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Johannes Gutenberg University Mainz, Mainz, Germany.
    Background: The objective of this study was to analyse the incidence of lip malignancies in Germany.

    Methods: Data from population-based cancer registries covering a population of 39 million inhabitants from 14 federal states were pooled. Lip malignancies were classified according to the International Classification of Diseases (ICD-10). Read More

    Curcumin and treatment of melanoma: The potential role of microRNAs.
    Biomed Pharmacother 2017 Feb 3;88:832-834. Epub 2017 Feb 3.
    Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
    Melanoma is the most aggressive type of skin cancer and is characterized by poor prognosis in its advanced stages because treatments are poorly effective and burdened with severe adverse effects. MicroRNAs (miRNAs) are small non-coding RNAs that are implicated in several cellular processes; they are categorized as oncogenic and tumor suppressor miRNAs. Several miRNAs are implicated in the pathogenesis and progression of melanoma, such as the tumor suppressor miR-let7b that targets cyclin D and regulates cell cycle. Read More

    Clinico-histopathological Survey of Head and Neck Cancer at Tertiary Health Care Centre -Dhulikhel Hospital.
    Kathmandu Univ Med J (KUMJ) 2016 Apr-Jun;14(54):167-171
    College of Dental Surgery, BP Koirala Institute of Health Sciences, Dharan Nepal.
    Background Head and neck is one of the most prevalent site for cancers along with lungs, cervix, breast and stomach. Hospital based cancer registries required for effective evaluation of diagnosis and management of cancer is inadequate in Nepal. Cancer registry system established by WHO is acquired by seven major hospitals in our country. Read More

    Clinical dosing regimen of selinexor maintains normal immune homeostasis and T cell effector function in mice: implications for combination with immunotherapy.
    Mol Cancer Ther 2017 Feb 1. Epub 2017 Feb 1.
    Cancer Immunology and Virology, Dana-Farber Cancer Institute
    Selinexor (KPT-330) is a first in class nuclear transport inhibitor currently in clinical trials as an anti-cancer agent. To determine how selinexor might impact anti-tumor immunity, we analyzed immune homeostasis in mice treated with selinexor and found disruptions in T cell development, a progressive loss of CD8 T cells and increases in inflammatory monocytes. Antibody production in response to immunization was mostly normal. Read More

    Promises and Dangers of Combination Therapy.
    Dig Dis 2017 1;35(1-2):56-60. Epub 2017 Feb 1.
    Evangelisches Krankenhaus Kalk, University of Cologne, Cologne, Germany.
    The efficiency of the existing methods of treating inflammatory bowel disease (IBD) is limited. There are 2 ways to address this problem - either create new treatment modalities or optimize current therapies. Optimisation may be accomplished by using combinations of established therapeutic strategies. Read More

    Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
    J Clin Rheumatol 2017 Feb 1. Epub 2017 Feb 1.
    From the *Clínica Angloamericana, Lima, Peru; †Instituto Peruano del Hueso y la Articulación, Lima, Peru; ‡Hospital Nacional Alberto Sabogal, Bellavista, Callao, Peru; §Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina; ∥Organización Médica de Investigación, Buenos Aires, Argentina; ¶Section of Rheumatology, Department of Medicine, Hospital Dr I Pirovano, Ciudad Autónoma de Buenos Aires, Argentina; #Universidade Federal do Paraná, Curitiba, Brazil; **Centro de Investigación Clínica de Morelia, Morelia, México; ††Centro de Reumatología y Ortopedia, Barranquilla, Colombia; ‡‡Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia; §§Pfizer Inc., Lima, Peru; ∥∥Pfizer Inc., Buenos Aires, Argentina; ¶¶Pfizer Inc., Collegeville, PA, USA; ##Pfizer Inc., New York, NY, USA; and ***Pfizer Inc., Groton, CT, USA.
    Objective: Rheumatoid arthritis (RA) is a chronic, autoimmune disease characterized by joint destruction. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post hoc analysis assessed the safety of tofacitinib in Latin American (LA) patients with RA versus the Rest of World (RoW) population. Read More

    Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
    Ann Rheum Dis 2017 Jan 31. Epub 2017 Jan 31.
    University of Hamburg, Hamburg, Germany.
    Objectives: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA.

    Methods: Data were pooled for all tofacitinib-treated patients (data cut-off: 31 March 2015). Read More

    The TLR3 Agonist Inhibit Drug efflux and Sequentially Consolidates Low-dose Cisplatin-based Chemoimmunotherapy while Reducing Side effects.
    Mol Cancer Ther 2017 Jan 30. Epub 2017 Jan 30.
    The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology and Hospital of Stomatology, Medical School, Nanjing University
    The traditional maximum dose density chemotherapy renders the tumor patients not only the tumor remission but the chemotherapy resistance and more adverse side effects. According to the widely positive expression of Toll-like receptor (TLR)-3 in oral squamous cell carcinoma (OSCC) patients (n=166), we here provided an alternative strategy involved the orderly treatment of TLR3 agonist polyinosine-polycytidylic acid (PIC) and low-dose cisplatin. The optimal dose of cisplatin, the novel role of PIC and the side effects of the combined chemotherapy were determined in vitro and in distinct human tumor models in vivo. Read More

    Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma.
    Am J Dermatopathol 2017 Feb;39(2):104-110
    *Department of General Pathology, Dental School, University of São Paulo, São Paulo, Brazil; †Department of Dermatology, School of Medicine, University of São Paulo, São Paulo, Brazil; ‡Department of Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil; and §Department of Pathology, Obrero Hospital, La Paz, Bolivia.
    Primary oral mucosal melanoma is an extremely rare and aggressive tumor arising from melanocytes located in the mucosal epithelium of the oral cavity. Although malignant melanoma of oral mucosa shares some clinical features with its cutaneous counterpart, it has been associated with a worst prognosis; its etiopathogenesis are still only partially unraveled as there is no influence of UV radiation. It is known that the mitogen-activated protein kinase pathway mediates cellular responses to growth signals and its activation is an important phenomenon in melanoma. Read More

    Sustained epidermal powder drug delivery via skin microchannels.
    J Control Release 2017 Jan 27;249:94-102. Epub 2017 Jan 27.
    Biomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Pharmacy Building, Room 480, Kingston, RI 02881, United States. Electronic address:
    Transdermal delivery of hydrophilic drugs is challenging. This study presents a novel sustained epidermal powder delivery technology (sEPD) for safe, efficient, and sustained delivery of hydrophilic drugs across the skin. sEPD is based on coating powder drugs into high-aspect-ratio, micro-coating channels (MCCs) followed by topical application of powder drug-coated array patches onto ablative fractional laser-generated skin MCs to deliver drugs into the skin. Read More

    Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual.
    CA Cancer J Clin 2017 Jan 27. Epub 2017 Jan 27.
    Chief, Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
    Answer questions and earn CME/CNE The recently released eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual, Head and Neck Section, introduces significant modifications from the prior seventh edition. This article details several of the most significant modifications, and the rationale for the revisions, to alert the reader to evolution of the field. The most significant update creates a separate staging algorithm for high-risk human papillomavirus-associated cancer of the oropharynx, distinguishing it from oropharyngeal cancer with other causes. Read More

    Effects of combined treatment with branched-chain amino acids, citric acid, L-carnitine, coenzyme Q10, zinc, and various vitamins in tumor-bearing mice.
    Biol Pharm Bull 2017 Jan 26. Epub 2017 Jan 26.
    Department of Surgery and Palliative Medicine, School of Medicine, Fujita Health University.
    A functional dietary supplement (FDS) containing Coenzyme Q10, Branched-chain Amino Acids and L-carnitine was administered to tumor-bearing mice, investigating its effects on tumor and muscle tissues. Experiment (A): B16 melanoma cells were implanted subcutaneously into the right side of the abdomen of 8- to 9-week-old C57BL/6J mice. The mice were divided into two groups: a FDS group that received oral administration of FDS (n=10), and a control group that received oral administration of glucose (n=10). Read More

    Metformin monotherapy in melanoma: A pilot, open-label, prospective and multicentric study indicates no benefit.
    Pigment Cell Melanoma Res 2017 Jan 25. Epub 2017 Jan 25.
    U1065, Centre Méditerranéen de Médecine Moléculaire, Team 1, Nice, France.
    Targeted therapies and immunotherapies have significantly improved the prognosis of patients with advanced melanoma (Long et al., 2015; Robert et al., 2015a; Robert et al. Read More

    Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014.
    JAMA 2017 01;317(4):388-406
    Institute for Health Metrics and Evaluation, University of Washington, Seattle.
    Introduction: Cancer is a leading cause of morbidity and mortality in the United States and results in a high economic burden.

    Objective: To estimate age-standardized mortality rates by US county from 29 cancers.

    Design And Setting: Deidentified death records from the National Center for Health Statistics (NCHS) and population counts from the Census Bureau, the NCHS, and the Human Mortality Database from 1980 to 2014 were used. Read More

    Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
    Gynecol Oncol 2017 Mar 17;144(3):571-576. Epub 2017 Jan 17.
    Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark. Electronic address:
    Objective: Few studies have examined the risk of an ovarian serous borderline tumor (SBT) associated with parity, infertility, oral contraceptives (OCs), or hormone replacement therapy (HRT), which was the study aim.

    Methods: This nationwide case-control study included all women with an SBT diagnosis in Denmark, 1978-2002. SBTs were confirmed by centralized expert pathology review. Read More

    Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
    Br J Haematol 2017 Jan 20. Epub 2017 Jan 20.
    Institute of Transfusion Medicine, Charité - University Hospital Berlin, Campus Virchow Clinic, Berlin, Germany.
    The increased risk of subsequent primary malignancies (SPM) in survivors of adult-onset Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains a challenging clinical problem worldwide. The German cancer registry database, pooled from 14 federal states, was used to calculate the standardized incidence ratio (SIR) and excess absolute risk (EAR) of SPM in 128 587 patients registered with first primary HL/NHL between 1990 and 2012. Conversely, SIRs were also calculated for a subsequent HL/NHL following other first cancers. Read More

    Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.
    JCI Insight 2017 Jan 12;2(1):e89140. Epub 2017 Jan 12.
    Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology.
    Tumor cells are thought to evade immune surveillance through interaction with immune cells. Much recent attention has focused on the modification of immune responses as a basis for new cancer treatments. SIRPα is an Ig superfamily protein that inhibits phagocytosis in macrophages upon interaction with its ligand CD47 expressed on the surface of target cells. Read More

    Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK.
    J Small Anim Pract 2017 Jan;58(1):10-16
    Animal Health Trust, Kentford, Newmarket CB8 7UU.
    Objectives: Oral malignant melanomas carry a poor-to-guarded prognosis because of their local invasiveness and high metastatic propensity. The Oncept melanoma vaccine is licensed to treat dogs with stage II or III locally-controlled oral malignant melanoma and this retrospective study aimed to assess survival of affected dogs treated with the vaccine in the UK.

    Material And Methods: Medical records of dogs with histopathologically-confirmed oral malignant melanoma that received the vaccine as part of their treatment were evaluated. Read More

    Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Oncogene 2017 Jan 16. Epub 2017 Jan 16.
    Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
    Despite remarkable progress in cutaneous melanoma genomic profiling, the mutational landscape of primary mucosal melanomas (PMM) remains unclear. Forty-six PMMs underwent targeted exome sequencing of 111 cancer-associated genes. Seventy-six somatic nonsynonymous mutations in 42 genes were observed, and recurrent mutations were noted on eight genes, including TP53 (13%), NRAS (13%), SNX31 (9%), NF1 (9%), KIT (7%) and APC (7%). Read More

    Melanoma in congenital melanocytic naevi.
    Br J Dermatol 2017 Jan 12. Epub 2017 Jan 12.
    Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London.
    Congenital melanocytic naevi (CMN) are a known risk factor for melanoma, with the greatest risk currently thought to be in childhood. There has been controversy over the years about the incidence, and therefore over clinical management of CMN, due partly to the difficulties of histological diagnosis and partly to publishing bias towards cases of malignancy. Large cohort studies have demonstrated that risk in childhood is related to the severity of the congenital phenotype, not only cutaneous but neuroradiological. Read More

    Review and proposal of regional surgical management for melanoma: revisiting of integumentectomy and incontinuity dissection in treatment of skin melanoma.
    Int J Clin Oncol 2017 Jan 7. Epub 2017 Jan 7.
    Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan.
    Background: Past studies showed that integumentectomy and incontinuity could be effective procedures in the surgical management of melanoma patients. The present study reports on the historical background of these procedures. In addition, we analyze the ICG assisted integumentectomy and incontinuity techniques and algorithms that we had created when performing this procedure. Read More

    More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients.
    World J Transplant 2016 Dec;6(4):658-664
    Andrew G Bostom, Division of Hypertension and Kidney Diseases, Department of Medicine, Rhode Island Hospital, Providence, RI 02903, United States.
    Non-melanoma cutaneous carcinomas, or skin cancers, predominantly squamous cell carcinomas (SCCs), are the most common malignancies occurring in kidney transplant recipients (KTRs). Squamous cell carcinoma risk is dramatically elevated in KTRs, occurring at rates of up 45-250 times those reported in general populations. New non-melanoma skin cancers in KTRs with a prior non-melanoma skin cancer also develop at 3-times the rate reported in non-KTRs with the same clinical history. Read More

    The Natural History And Patterns Of Metastases From Mucosal Melanoma: An Analysis Of 706 Prospectively-Followed Patients.
    Ann Oncol 2016 Dec 29. Epub 2016 Dec 29.
    1 Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China;
    Background: We examined whether mucosal melanomas are different in their clinical course and patterns of metastases when arising from different anatomic sites. Our hypothesis was that metastatic behavior would differ from primary mucosal melanomas at different anatomical sites.

    Patients And Methods: Clinical and pathological data from 706 patients were compared for their stage distribution, patterns of metastases, CKIT/BRAF mutation status, and overall survival for different anatomical sites. Read More

    Long-term outcomes after carbon-ion radiotherapy for oral mucosal malignant melanoma.
    J Radiat Res 2016 Dec 26. Epub 2016 Dec 26.
    Department of Otolaryngology, Chiba University Graduate School of Medicine, 1-8-1 Inohara, Chuo-ku, Chiba 260-8677, Japan.
    Oral mucosal malignant melanoma (OMM) is extremely rare and has a poor prognosis. Owing to its rarity, it has not yet been possible to establish an optimal treatment modality. The objective of this study was to evaluate the long-term efficacy of carbon-ion radiotherapy (C-ion RT) for OMM. Read More

    Targeting metastasis-initiating cells through the fatty acid receptor CD36.
    Nature 2017 Jan 7;541(7635):41-45. Epub 2016 Dec 7.
    Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain.
    The fact that the identity of the cells that initiate metastasis in most human cancers is unknown hampers the development of antimetastatic therapies. Here we describe a subpopulation of CD44(bright) cells in human oral carcinomas that do not overexpress mesenchymal genes, are slow-cycling, express high levels of the fatty acid receptor CD36 and lipid metabolism genes, and are unique in their ability to initiate metastasis. Palmitic acid or a high-fat diet specifically boosts the metastatic potential of CD36(+) metastasis-initiating cells in a CD36-dependent manner. Read More

    Immune-related alopecia (areata and universalis-type) in cancer patients receiving immune checkpoint inhibitors.
    Br J Dermatol 2016 Dec 11. Epub 2016 Dec 11.
    Dermatology Service, Institut Universitaire du Cancer.
    CTLA-4, PD-1, and PD-L1 monoclonal antibodies, commonly known as immune checkpoint inhibitors, are used for the treatment of various malignancies. The mechanism of action involves the inhibition of negative regulators of immune activation, which results in many patients developing immune-related adverse events (irAEs) including endocrinopathies, pneumonitis, colitis, hepatitis and dermatologic events. Dermatologic irAEs include maculopapular rash, pruritus, vitiligo, blistering disorders, mucocutaneous lichenoid eruptions, rosacea, and exacerbation of psoriasis. Read More

    Optimal multidisciplinary treatment of oral cavity mucosal melanoma: outcome analysis in a case series.
    Anticancer Drugs 2017 Mar;28(3):327-334
    aMedical Oncology Unit, POC SS Annunziata, Taranto bDepartment of Otolaryngology, Otolaryngology and Maxillo-Facial Unit cDepartment of Pathology, Dermatology Unit dDepartment of Dermatology, Pathology Unit, University of Bari, Bari eDepartment of Biostructures and Bioimages, University of Naples 'Federico II' fDepartment of Clinical Medicine and Surgery, University Federico II gOtolaryngology Unit, National Tumour Institute of Naples 'Foundation G. Pascale', Naples, Italy hLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, USA.
    Oral cavity mucosal melanomas (OCMM) represent only 3% of all malignant melanomas. Surgery is the mainstay of treatments and it is often followed by adjuvant radiotherapy. The role of adjuvant immunotherapy and/or chemotherapy is still debated and to date neither treatment is routinely used. Read More

    Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
    J Cancer Res Clin Oncol 2017 Mar 5;143(3):439-445. Epub 2016 Dec 5.
    Columbia University Medical Center, New York, NY, USA.
    Purpose: Clinical trials commonly use physician-adjudicated adverse event (AE) assessment via the common terminology criteria for adverse events (CTCAE) for decision-making. Patient-reported health-related quality of life (HRQoL) data are becoming more frequent in oncology; however, the relationship between physician-adjudicated AE assessment and HRQoL is understudied.

    Methods: Data from a phase II trial (clinicaltrials. Read More

    A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo.
    Cancer Prev Res (Phila) 2017 Jan 5;10(1):36-44. Epub 2016 Dec 5.
    Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.
    Oxidative stress plays a role in UV-induced melanoma, which may arise from melanocytic nevi. We investigated whether oral administration of the antioxidant N-acetylcysteine (NAC) could protect nevi from oxidative stress in vivo in the setting of acute UV exposure. The minimal erythemal dose (MED) was determined for 100 patients at increased risk for melanoma. Read More

    FHOD1 formin is upregulated in melanomas and modifies proliferation and tumor growth.
    Exp Cell Res 2017 Jan 2;350(1):267-278. Epub 2016 Dec 2.
    Department of Pathology and Forensic Medicine, University of Turku and Turku University Hospital, Turku, Finland; MediCity Research Laboratory, University of Turku, Finland. Electronic address:
    The functional properties of actin-regulating formin proteins are diverse and in many cases cell-type specific. FHOD1, a formin expressed predominantly in cells of mesenchymal lineage, bundles actin filaments and participates in maintenance of cell shape, migration and cellular protrusions. FHOD1 participates in cancer-associated epithelial to mesenchymal transition (EMT) in oral squamous cell carcinoma and breast cancer. Read More

    Effects of fatty acid synthase inhibitors on lymphatic vessels: an in vitro and in vivo study in a melanoma model.
    Lab Invest 2017 Feb 5;97(2):194-206. Epub 2016 Dec 5.
    Department of Oral Diagnosis, School of Dentistry of Piracicaba, State University of Campinas (UNICAMP), Piracicaba, Brazil.
    Fatty acid synthase (FASN) is responsible for the endogenous production of fatty acids from acetyl-CoA and malonyl-CoA. Its overexpression is associated with poor prognosis in human cancers including melanomas. Our group has previously shown that the inhibition of FASN with orlistat reduces spontaneous lymphatic metastasis in experimental B16-F10 melanomas, which is a consequence, at least in part, of the reduction of proliferation and induction of apoptosis. Read More

    BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Pathology 2017 Jan 30;49(1):55-61. Epub 2016 Nov 30.
    Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
    Head and neck mucosal melanoma (HNMuM), which occurs mostly in the sinonasal and oral cavity, constitutes less than 1% of all malignant melanomas. Treatment options fail to improve the prognosis of this aggressive tumour that has low overall survival rates. Thus, development of new targeted therapies is essential. Read More

    PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report.
    J Immunother Cancer 2016 15;4:83. Epub 2016 Nov 15.
    Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI USA.
    Background: Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC). The use of such therapies has also been introduced into the treatment of other malignancies, including head and neck cancer. The combined effects of checkpoint inhibitors and anti-PD1(L1) antibodies and radiation therapy have not yet been sufficiently investigated. Read More

    Eight Years' Experience of Sentinel Lymph Node Biopsy in Melanoma Using Lymphoscintigraphy and Gamma Probe Detection After Radiocolloid Mapping.
    Dermatol Surg 2017 Feb;43(2):287-292
    *Department of Oral and Maxillofacial Surgery, NHE-CHU de Clermont-Ferrand, Université d'Auvergne, Clermont-Ferrand, France; †UMR Inserm/UdA, U1107, Neuro-Dol, Trigeminal Pain and Migraine, Université d'Auvergne, Clermont-Ferrand, France; ‡Department of Biostatistics, DRCI-CHU de Clermont-Ferrand, Université d'Auvergne, Clermont-Ferrand, France; §Department of Dermatology, NHE-CHU de Clermont-Ferrand, Université d'Auvergne, Clermont-Ferrand, France.
    Background: Isosulfan blue dye peripheral injection is used in preoperative sentinel lymph node (SLN) identification alone or, to increase sensitivity, in conjunction with radiocolloid mapping. However, isosulfan blue dye has certain drawbacks and limitations.

    Objective: This study assesses the authors' experience of SLN biopsy using only radiocolloid tracer. Read More

    Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma.
    Cancer Immunol Immunother 2016 Nov 26. Epub 2016 Nov 26.
    Biotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
    Adoptive immunotherapy using cytokine-induced killer (CIK) cells has shown potential antitumor ability against several kinds of cancers, including melanoma. However, little is known about the achievable outcome of CIK cells in melanoma patients at different pathological stages. Here we recruited 55 patients treated with conventional therapy plus CIK cells as the CIK group, and 49 patients treated with conventional therapy alone as the control group. Read More

    Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    BMC Cancer 2016 Nov 25;16(1):918. Epub 2016 Nov 25.
    Experimental Pharmacology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione G. Pascale," IRCCS, Naples, Italy.
    Background: Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage. Thus, the concomitant use of novel compounds represents a critical strategy to improve treatment results. Histone deacetylase inhibitors (HDACi) enhance the activity of several anticancer drugs including cisplatin and anti-Epidermal Growth Factor Receptor (anti-EGFR) compounds. Read More

    Socioeconomic status and site-specific cancer incidence, a Bayesian approach in a French Cancer Registries Network study.
    Eur J Cancer Prev 2016 Nov 22. Epub 2016 Nov 22.
    aU1086 INSERM-UCBN, 'Cancers & Preventions', Team labeled 'League against Cancer', Caen bIsere Cancer Registry, CHU, Grenoble cTarn Cancer Registry, Claudius Regaud Institute dFrench Network of Cancer Registries, Toulouse, France.
    The aim of this study was to identify and compare cancer sites whose incidence is influenced by social deprivation. The study population comprised 189 144 cases of cancer diagnosed between 2006 and 2009, recorded in member registries of the French Network of Cancer Registries. Social environment was assessed at an aggregate level using the European Deprivation Index. Read More

    An update on the current management of head and neck mucosal melanoma.
    J Oral Pathol Med 2016 Nov 19. Epub 2016 Nov 19.
    Department of Oral & Maxillofacial Surgery, Queen Alexandra Hospital, Portsmouth, UK.
    Primary mucosal melanomas of the head and neck are rare and aggressive tumours that arise in the nasal cavity, paranasal sinuses and more rarely in the oral cavity. The current treatment options include radical surgical resection with adjuvant external beam radiotherapy being offered in high-risk patients. Although the latter can improve regional control, it does not reduce overall survival. Read More

    Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines.
    J Laryngol Otol 2016 May;130(S2):S125-S132
    Department of Otolaryngology-Head and Neck Surgery,Manchester Royal Infirmary,Oxford Road,Manchester,UK.
    This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides consensus recommendations on the management of cutaneous basal cell carcinoma and squamous cell carcinoma in the head and neck region on the basis of current evidence. Recommendations • Royal College of Pathologists minimum datasets for NMSC should be adhered to in order to improve patient care and help work-force planning in pathology departments. Read More

    Anticancer effects of Ixeris dentata (Thunb. ex Thunb.) nakai extract on human melanoma cells A375P and A375SM.
    J Ethnopharmacol 2016 Dec 8;194:1022-1031. Epub 2016 Nov 8.
    Department of Companion and Laboratory Animal Science, Kongju National University, Yesan 340-702, South Korea. Electronic address:
    Ethnopharmacological Relevance: The plant species Taraxacum coreanum (TC), Youngia sonchifolia (YS), and Ixeris dentata (ID) belong to the family Compositae and are used for medicinal purposes in traditional medicine. However, the anticancer effects of TC, YS, and ID extracts and the underlying molecular mechanisms in melanoma cells have not been elucidated.

    Aim Of The Study: To investigate the potential anticancer effects of TC, YS, and ID extracts on human melanoma cells and explore the potential pharmacological mechanisms in vitro and in vivo. Read More

    Oral melanoma: Relevance to the dental team members.
    J Am Dent Assoc 2017 Feb 9;148(2):113-119. Epub 2016 Nov 9.
    Background And Overview: Oral melanomas vary in color and morphology and resemble myriad other reactive, benign, or malignant conditions. The authors describe a case report of a patient with a primary oral melanoma that presented as a nonspecific ulcer, which showed nodal metastasis during resection.

    Case Description: A 64-year-old man who was examined by his periodontist to assess implant healing had a reddish-purple ulcer of the maxillary mucosa of 3 to 4 weeks duration. Read More

    Validation and development of MTH1 inhibitors for treatment of cancer.
    Ann Oncol 2016 Dec 8;27(12):2275-2283. Epub 2016 Nov 8.
    Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics
    Background: Previously, we showed cancer cells rely on the MTH1 protein to prevent incorporation of otherwise deadly oxidised nucleotides into DNA and we developed MTH1 inhibitors which selectively kill cancer cells. Recently, several new and potent inhibitors of MTH1 were demonstrated to be non-toxic to cancer cells, challenging the utility of MTH1 inhibition as a target for cancer treatment.

    Material And Methods: Human cancer cell lines were exposed in vitro to MTH1 inhibitors or depleted of MTH1 by siRNA or shRNA. Read More

    1 OF 68